Estudios Clínicos

En esta sección encontrará los estudios clínicos más recientes, los cuales avalan la calidad, eficacia y efectividad de los principios activos de nuestros medicamentos.

Empagliflozina

Sacubitrilo Valsartán

Sacubitrilvalsartan in a wide spectrum of heart failure patients. 2025

Sacubitril Valsartan vs ACE Inhibitors or ARBs. 2025

Characteristics, Predictors, and Clinical Outcomes in heart failure with reduced ejection fraction according to a 1 year LVEF following sacubitril valsartan treatment

Uptitration of Sacubitril Valsartan and Outcomes

Kidney Outcomes: ARNI vs. ACE Inhibitors

TRANSITION Study

TITRATION

PIONEER HF

PARAGON HF

PARADIGM-HF

Docherty PARADIGM HF2

Sacubitril valsartan role in patients with resistant hypertension: a systematic review

Effectiveness and safety of SGLT2i initiation in sacubitril-valsartan users with HF a population-based cohort study

Ten years real-world experience with sacibitril valsartan in patients with HFrFE

Empagliflozina

Diabetes

Diabetic Agents, From Metformin

EMPA KIDNEY

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Empare reduced en español JACC

EMPULSE

Gliflozins From Antidiabetic Drugs to Cornerstone in Heart

Safety of Empagliflozin in

SGLT2 Inhibitors Statins or ACE Inhibitors of the 21st Century

SGLT2 Inhibitors the Statins of the 21st Century

The EMPEROR Reduced Trial

The role of SGLT2 I in vascular aging

Insuficiencia Cardiaca

2022 AHA ACC HFSA Guideline for ICC resumen

Guía ESC 2021 Full text

Guía manejo ICC AHA full text

Iacoviello – Recent advances in pharmacological treatment of heart failure

ADA 2023 Pharmacologic Approaches

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with
chronic kidney disease

Efficacy of Sodium-Glucose 2 Transporter
Inhibitors in Heart Failure With Preserved
Ejection Fraction

Enfermedad Renal

Cardiorenal Syndrome Classification Pathophysiology Diagnosis and Treatment Strategies A Scientific Statement From the American Heart Association

KDIGO 2022

Management of Heart Failure in Patients with Chronic Kidney Disease

Synopsis KDIGO 2022

Use of Glucose Lowering Agents